Grady is pointing at one of AI's most credible promises: closing the expertise gap between elite cancer centers and community oncology. On the merits, we agree — diagnostic support is where models already show measurable clinical value, not just chatbot novelty. But 'MSK-caliber' is a high bar to claim: prospective validation, regulatory clearance and clinician trust matter far more than demo-day accuracy numbers. It's also telling when a Sequoia partner flags a vertical like this — it signals where smart money sees durable moats, namely regulated, data-rich domains where generic AI tools can't simply walk in. Expect more capital chasing clinical AI through 2026.